Cargando…
Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives
Immune checkpoint inhibitors (ICIs) have shown remarkable benefit in the treatment of patients with non-small-cell lung cancer (NSCLC) and have emerged as an effective treatment option even in the first-line setting. ICIs can block inhibitory pathways that restrain the immune response against cancer...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The Korean Association of Immunologists
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049584/ https://www.ncbi.nlm.nih.gov/pubmed/32158598 http://dx.doi.org/10.4110/in.2020.20.e10 |